Table 2.
Deregulated miRNAs and their target genes identified in Cluster 3 & 10 and Cluster 4 & 11 that were down-regulated at all Cu treatment groups (>1.5-fold up/down-regulated, p<0.05) a. These clusters are derived from our previous study.10
| Cluster 3 & 10 | |||
|---|---|---|---|
| Gene targets | Gene target FC (Cu dose) | miRNA | miRNA FC |
| parvalbumin 8 | 0.09 (high) | miR-203a | 3.91 |
| miR-199* | 2.63 | ||
| s100 calcium binding protein z (zgc:110464) | 0.11 (high) | miR-16a | 2.50 |
| miR-16c | 2.03 | ||
| similar to protein phosphatase 1, regulatory (inhibitor) subunit 3C like | 0.18 (high) | miR-16c | 2.03 |
| olfactory marker protein b | 0.18 (high) | miR-193b | 0.36 |
| calbindin 2, like | 0.21 (high) | miR-25 | 2.27 |
| similar genes: | |||
| ATPase, Na+/K+ transporting, beta 1a polypeptide | 0.60 (med) | miR-126 | 2.24 |
| 0.62 (high) | miR-126 | 2.85 | |
| miR-25 | 2.27 | ||
| Suppressor of cytokine signaling 1 (zgc:91868) b | 0.35; 0.31 (med) | miR-7a | 4.68 |
| 0.11; 0.08 (high) | miR-203a | 3.91 | |
| miR-30c | 2.88 | ||
| miR-203b | 2.47 | ||
| miR-16c | 2.03 | ||
| Cluster 4 & 11 | |||
| dopey family member 2 (zgc:63622) b | 0.29; 0.27; 0.18 (med) | miR-458 | 3.01 |
| 0.28; 0.25; 0.16 (high) | miR-458 | 4.08 | |
| zona pellucida glycoprotein 2.2 | 0.47 (high) | miR-16a | 2.50 |
| miR-128 | 1.52 | ||
| miR-193b | 0.36 | ||
| zona pellucida glycoprotein 3a.1 | 0.56 (med) | miR-214 | 0.48 |
| 0.53 (high) | miR-214 | 0.41 | |
| sulfotransferase family 2, cytosolic sulfotransferase 1 | 0.20 (high) | miR-27b | 1.57 |
| odorant receptor, family 5, member 1 | 0.26 (med) | miR-183 | 0.48 |
| 0.25 (high) | miR-183 | 0.55 | |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha a | 0.62 (med) | let-7g | 2.04 |
| 0.47 (high) | let-7g | 2.92 | |
| let-7h | 1.90 | ||
| growth arrest and DNA-damage-inducible, beta b | 0.45;0.36 (high) | miR-16a | 2.50 |
| miR-25 | 2.27 | ||
| miR-16c | 2.03 | ||
| claudin d | 0.41 (med) | miR-214 | 0.48 |
| 0.40 (high) | miR-16a | 2.50 | |
| miR-16c | 2.03 | ||
| miR-214 | 0.41 | ||
| MpV17 transgene, murine homolog, glomerulosclerosis b | 0.62; 0.55; 0.40 (med) | let-7i | 1.98 |
| 0.56; 0.54; 0.40 (high) | miR-146a | 5.14 | |
| let-7f | 3.10 | ||
| let-7i | 2.36 | ||
| let-7h | 1.90 | ||
| dual specificity phosphatase 1 | 0.62 (low) | miR-140* | 0.50 |
| 0.47 (med) | miR-140* | 0.45 | |
| 0.44 (high) | miR-140* | 0.34 | |
| cyclin-dependent kinase inhibitor 3 | 0.41 (med) | miR-140* | 0.45 |
| 0.44 (high) | miR-16c | 2.03 | |
| miR-23a | 1.60 | ||
| miR-140* | 0.34 | ||
| fatty acid binding protein 10, liver basic | 0.39 (med) | miR-183 | 0.48 |
| 0.45 (high) | miR-183 | 0.55 | |
| miR-193b | 0.36 | ||
| odorant receptor, family 2, member 10 | 0.54 (med) | miR-214 | 0.48 |
| 0.47 (high) | miR-199* | 2.63 | |
| miR-214 | 0.41 | ||
a
Data represents only those miRNAs >1.5-fold up-regulated (red), or down-regulated (green) with a statistical significance of p<0.05 and Log2 average expression >5. Down-regulation is indicated as present of control. FC=fold-change.
b
More than one probe were used for the same gene target.